期刊文献+

药物结合心理行为治疗精神分裂症伴代谢综合征的效果分析 被引量:17

The effective analysis of schizophrenia complicated with metabolic syndrome treated by medication and psycho-behavior therapy
下载PDF
导出
摘要 目的探讨以药物结合心理行为的综合干预措施治疗精神分裂症伴代谢综合征的临床效果。方法将100例精神分裂症伴代谢综合征的患者随机分为干预组和对照组各50例。2组均给予齐拉西酮抗精神病治疗,干预组在此基础上加用二甲双胍结合心理行为的综合干预措施,随访6个月。采用阳性与阴性症状量表(PANSS)评估疗效,生活质量综合评定问卷(GQOLI-74)评估生活质量,同时比较2组患者代谢综合征的各项指标、复发率和再入院率。结果 2组患者入组时PANSS评分、GQOLI-74评分和代谢指标异常比较差异均无统计学意义(P>0.05),随访6个月时2组PANSS各项评分较治疗前均有明显改善,且组间比较差异有统计学意义(P<0.05);2组GQOLI-74躯体功能、心理功能及社会功能评分均较治疗前明显提高,差异有统计学意义(P<0.05),其中干预组躯体功能、心理功能指标明显高于对照组,差异有统计学意义(P<0.05);2组代谢综合征相关指标异常比例均降低,其中干预组各项指标异常比例明显低于对照组,差异有统计学意义(P<0.05或P<0.01);6个月内干预组复发率10.00%(5例),再住院率8.00%(4例),明显低于对照组的复发率26.00%(13例)和再住院率22.00%(11例),差异有统计学意义(χ2=4.33、3.84,P<0.05)。结论药物结合心理行为的综合性干预措施治疗精神分裂症伴代谢综合征患者,可明显提高治疗效果,并明显改善代谢综合征各项指标,提高生活质量,降低复发率和再入院率。 Objective To explore the effects of medication and psycho-behavior therapy on schizophrenia complicated with metabolic syndrome.Methods One hundred schizophrenia Patients complicated with metabolic syndrome were randomly divided into intervention group and control group,50 cases in each group.In addition to ziprasidone antipsychotic medication for both groups,the intervention group received psycho-behavior therapy for 6months.The positive and negative symptom scale(PANSS)was performed to assess curative effect,and general quality of life inventory(GQOLI-74)was used to evaluate physical function,psychological function and social function.At the same time,the rate of recurrence and readmission was comparatively analyzed between two groups.Results There was no significant difference between two groups before treatment in terms of PANSS scores,GQOLI-74 scores and abnormal metabolic scores(P〈0.05),all of which were obviously improved after 6-month therapy in both groups(P〈0.05);Furthermore,after therapy,and the intervention group got the higher scores of physical function and psychological function,higher PANSS scores and less abnormal metabolic scores compared with control group(all P〈0.05).The rate of recurrence and rate of readmission observed within 6months in intervention group were 10%(5cases)and 8%(4cases),which were significantly lower than 26%(13cases),22%(11cases)observed in the control group with statistically significant differences(!2=4.33,3.84;P〈0.05).Conclusion The therapy of medication combined with psycho-behavior therapy can significantly improve the therapeutic effects and metabolic indicators to improve the quality of life and reduce the rate of recurrence and readmission in schizophrenia patients complicated with metabolic syndrome.
出处 《中国实用神经疾病杂志》 2016年第2期1-3,共3页 Chinese Journal of Practical Nervous Diseases
基金 梅州市科技局计划项目(项目编号:2012B115)
关键词 精神分裂症 代谢综合征 齐拉西酮 心理行为治疗 Schizophrenia Metabolic syndrome Ziprasidone Psycho-behavior therapy
  • 相关文献

参考文献15

  • 1Ambiel MV, Roselino AM. Prevalence of metabolic syndrome and its components in a Brazilian sample of pemphigus patients [J]. An Bras Dermatol,2014,89(5):752-756.
  • 2Lasig D,Bevanda M,Bonjak N,et al. Metabolic syndrome and inflammation markers in patients with schizophrenia and re- current depressive disorder[J]. Psychiatr Danub, 2014,26 (3) : 214-219.
  • 3杨忠,周联军,赵彩云,祝敬溪.长期住院慢性精神分裂症患者伴发代谢综合征的临床研究[J].当代医学,2011,17(6):62-63. 被引量:10
  • 4Saddichha S, Manjunatha N, Ameen S, et al. Metabolic syn- drome in first episode schizophrenia-A randomized doubleblind controlled, short-term prospective study [J]. Schizophr Res, 2008, I01 (1/3) ; 266-272.
  • 5Larsen JT, Fagerquist M, Holdrup M, et al. Metabolic syn- drome and psychiatrists choice of follow- up interventions in patients treated with atypical antipsyehotics in denmark and Sweden[J]. Nord J Psychiatry,2011,65(1) :40-46.
  • 6Jia WP,Xiang KS, Chen L, et al. Epidemiological study on obe- sity and its eomorbidities in urban Chinese older than 20 years of age in Shanghai,China[J]. Obes Rev,2002,3(3) :157-165.
  • 7Stone WS, Faraone SV, Su J, et al. Evidence for linkage be- tween regulatory enzymes in and schizophrenia in a multiplex sample[J]. Am J Med Genet B Neuropsychiatr Genet, 2004, 127(1) :5-10.
  • 8尹又,谭立文.精神分裂症可能的内表型之一:糖代谢异常[J].国际精神病学杂志,2006,33(1):48-50. 被引量:9
  • 9朱海兵,李洁,邱畅,黄杏梅,党亚梅,刘学军,王丹逢,林育华.首发精神分裂症伴发胰岛素抵抗的临床分析[J].中国临床实用医学,2008,2(3):1-3. 被引量:4
  • 10Zimmet P. Epidemiology of diabetes mellitus and associated cardiovascular risk factors:focus on human immunodeficiency virus and psychiatric disorders [J]. Am J Med, 2005, 118 ($2) : 3S-8S.

二级参考文献14

  • 1乔颖,闻晖,陈海莹,项志清,薛振康,宋振华,黄继忠.长期住院治疗的精神分裂症患者代谢综合征风险研究[J].上海精神医学,2008,20(2):65-68. 被引量:21
  • 2中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中国糖尿病杂志,2004,12(3):156-161. 被引量:3043
  • 3孙国祥,周正元,吴国强,程良保,徐敏皋,李建清,张钧,胡一河.苏州地区居民代谢综合征流行病学调查[J].中国慢性病预防与控制,2006,14(3):215-216. 被引量:10
  • 4Saari K,Linddeman S,Viilo KM,et aI.A 4-fold risk of metabolic syndrome in patients with schizophrenia;the Northern Finland 1966 birth cohort study[J].J Clin Psychiatry,2005 66(5):559 565.
  • 5Ryan MC, Collins P, Thakore JH, et al. Impaired fasting glucose tolerance in firstepisode, drug-nave patiences with schizophrenia[J].Am J Psychiatry, 2005,160:284-289.
  • 6Gu D,Reynolds K,Wu X,et al.Prevalence of the metabolic syndrome and overweight among adults in China[J] Lancet 2005,365(9468).1398-1405.
  • 7Ardern CI, Katzmarzyk PT, Janssenl, et al. Discriminations of health risk by combined body mass index and waist cfrcumference[J].Obesity Ees, 2005, 11(1):135-142.
  • 8McEvoy JP, Meyer JM, Goff DO, et al.Prevalence of the metabolicsyndrome in patients with schizophrenia: basefine results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophreniatrial and comparison with national estimates from NHANES Ⅲ [J].Schizophr Ees,2005,80(1):19.
  • 9Newcomer JW. Metabolic considerations in the use of antipsychotic medications:a review of recent evidence[J].J Clin Psychiatry,200768(Supp 1).20-27.
  • 10田伟伟,郑广娟.代谢综合征与心血管疾病的关系[J].中西医结合心脑血管病杂志,2009,7(1):82-84. 被引量:6

共引文献24

同被引文献165

引证文献17

二级引证文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部